Nationwide Multicenter Observational Study of FOLFIRINOX Chemotherapy in 399 Patients With Unresectable or Recurrent Pancreatic Cancer in Japan-Reference-Cited by-同舟云学术

Nationwide Multicenter Observational Study of FOLFIRINOX Chemotherapy in 399 Patients With Unresectable or Recurrent Pancreatic Cancer in Japan

Published:2018-05 Issue:5 Volume:47 Page:631-636
ISSN:1536-4828
Container-title:Pancreas
language:en
Short-container-title:Pancreas

Author:

Todaka Akiko,Mizuno Nobumasa,Ozaka Masato,Ueno Hideki,Kobayashi Satoshi,Uesugi Kazuhiro,Kobayashi Noritoshi,Hayashi Hideyuki,Sudo Kentaro,Okano Naohiro,Horita Yosuke,Kamei Keiko,Yukisawa Seigo,Nakamori Shoji,Yachi Yutaka,Henmi Toshiyuki,Kobayashi Marina,Boku Narikazu,Mori Keita,Fukutomi Akira

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Endocrinology,Hepatology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference15 articles.

1. European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women?;Ann Oncol,2015

2. Cancer statistics, 2015;CA Cancer J Clin,2015

3. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial;J Clin Oncol,1997

4. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group;J Clin Oncol,2007

5. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer;N Engl J Med,2011

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FOLFIRINOX in Pancreatic Cancer: Risk Factors for Febrile Neutropenia and Severe Neutropenia — Nationwide Study Analysis;Anticancer Research;2023-08-30

2. Real-world dose reduction of standard and modified FOLFIRINOX in metastatic pancreatic cancer: a systematic review, evidence-mapping, and meta-analysis;Therapeutic Advances in Medical Oncology;2023-01

3. Prognostic Analysis of Distal Pancreatectomy for Pancreatic Body and/or Tail Cancer Involving the Portal Vein;Pancreas;2022-05

4. Prognostic Factors for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer Receiving Neoadjuvant FOLFIRINOX;Gut and Liver;2021-03-15

5. FOLFIRINOX for Recurrent Pancreatic Cancer After Pancreatic Resection;Pancreas;2020-10-13